Cellectis (NASDAQ:CLLS) Share Price Passes Below 50-Day Moving Average – Should You Sell?

Cellectis S.A. (NASDAQ:CLLS)’s stock price crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $3.50 and traded as low as $2.79. Cellectis shares last traded at $2.94, with a volume of 21,957 shares changing hands.

Wall Street Analyst Weigh In

Several research firms have issued reports on CLLS. Citizens Jmp reiterated a “market outperform” rating and set a $8.00 target price on shares of Cellectis in a research report on Tuesday, April 14th. Barclays began coverage on Cellectis in a report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Cellectis presently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Cellectis Price Performance

The stock’s fifty day moving average price is $3.50 and its 200-day moving average price is $3.81. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.52 and a current ratio of 1.52. The firm has a market cap of $295.00 million, a PE ratio of -4.39 and a beta of 2.86.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.08. Cellectis had a negative net margin of 89.51% and a negative return on equity of 80.66%. The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $11.04 million.

Institutional Investors Weigh In On Cellectis

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Cellectis in the 4th quarter worth approximately $15,385,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Cellectis by 228.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock valued at $5,856,000 after purchasing an additional 3,284,409 shares in the last quarter. Marshall Wace LLP raised its holdings in Cellectis by 1,610.3% during the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock worth $864,000 after purchasing an additional 168,038 shares during the last quarter. Citadel Advisors LLC acquired a new position in Cellectis during the third quarter worth $633,000. Finally, Millennium Management LLC boosted its position in Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 22,080 shares in the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.